Canada Markets closed

PharmaTher Holdings Ltd. (PHRM.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.6100+0.0200 (+3.39%)
At close: 3:59PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

    Leading U.S.-based CDMO to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.Expected FDA clinical and commercial supply in H2-2022.Unlocking potential partnership opportunities with research labs, clinics and pharmaceutical companies globally. TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announces it

  • GlobeNewswire

    PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

    Achieving its second FDA orphan drug designation with ketamine.Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation.Seeking to enter Phase 2 clinical trial in 2022. TORONTO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug desi

  • GlobeNewswire

    PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

    “KET-LID” trial to evaluate ketamine’s safety and efficacy in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s diseaseTORONTO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2 KET-LID clinical trial of Ketamine for the treatment of Levodopa-Induced Dyskinesia in Subjects with Parkinson’s Disease. Patient sc